Bukwang Pharm. Ind. Co., Ltd. Receives First Performance Milestone Payment From Bukwang Pharm. Ind. Co., Ltd.
EXTON, Pa.--(BUSINESS WIRE)--Melior Discovery, Inc. announced today that it has received the first of a series of potential performance milestone payments as part of a licensing arrangement with Bukwang Pharmaceutical Co., Ltd of South Korea to develop, manufacture and commercialize Melior’s lead compound MLR-1023, a first-in-class insulin sensitizer for the treatment of type 2 diabetes.
Melior has received protocol approval from the US FDA to enter into a Phase 2 proof-of-concept study in type 2 diabetic patients. The 4-week protocol will enroll 120 subjects across 14 clinical sites in the U.S. and Korea. The recognition by the US FDA of clinical trial data generated by Pfizer more than 30 years ago for an alternative therapeutic use was pivotal in achieving this regulatory goal.
Help employers find you! Check out all the jobs and post your resume.
Melior has received protocol approval from the US FDA to enter into a Phase 2 proof-of-concept study in type 2 diabetic patients. The 4-week protocol will enroll 120 subjects across 14 clinical sites in the U.S. and Korea. The recognition by the US FDA of clinical trial data generated by Pfizer more than 30 years ago for an alternative therapeutic use was pivotal in achieving this regulatory goal.
Help employers find you! Check out all the jobs and post your resume.